In this issue of Blood, Schroeder et al1 from the Kreitman team at the National Cancer Institute build on their already strong track record in clinical research on hairy cell leukemia (HCL) by reporting valuable prospective data on 2 chemoimmunotherapy regimens, DCFR (pentostatin [alias deoxycoformycin (DCF)] plus rituximab) and BR (bendamustine + rituximab), for patients with relapsed or refractory (R/R) HCL.
An old but still good friend: chemoimmunotherapy in HCL
Tiacci, Enrico;Mancini, Alessandro
2026
Abstract
In this issue of Blood, Schroeder et al1 from the Kreitman team at the National Cancer Institute build on their already strong track record in clinical research on hairy cell leukemia (HCL) by reporting valuable prospective data on 2 chemoimmunotherapy regimens, DCFR (pentostatin [alias deoxycoformycin (DCF)] plus rituximab) and BR (bendamustine + rituximab), for patients with relapsed or refractory (R/R) HCL.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
